spacer
home > epc > summer 2002 > the trials and tribulations of importing clinical trials materials into europe
PUBLICATIONS
European Pharmaceutical Contractor

The Trials and Tribulations of Importing Clinical Trials Materials into Europe

There are a number of key areas that international pharmaceutical companies will need to consider when planning to conduct clinical studies in Europe. Perhaps most importantly, companies need to be aware of several forthcoming regulatory changes, which will be implemented in the next three years as a result of the adoption of the Clinical Trial Directive (2001/20/EC of the European Parliament and of the Council).

Currently, there is no unified regulation governing the import and movement of material around Europe. Local country regulations apply, which in some countries can be as simple as a notification, while in others a formal application is needed. In the UK, for example, all the details of the study materials would be included in the CTX application.

In general terms, the manufacture of clinical materials is not presently required to comply with GMP, but there are some notable exceptions - Germany, for instance, which applies the same GMP to clinical trial materials (CTM) as to a marketed product.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keren Winmill, Director of Clinical Trial Supplies at Penn Pharmaceutical Services

Keren Winmill is a Pharmacist with 24 years of experience in the pharmaceutical industry. She joined Penn Pharmaceutical Services in 1990 to manage the clinical supplies unit. Keren spent 12 years with Ciba Geigy in Switzerland and in the UK in regulatory affairs, business development and marketing positions.

Keren subsequently joined Quintiles as Director of Business Development, returning to Penn in 1999 as Director of the Clinical Supplies Business Unit. She is responsible for clinical trial packaging and supply management.

spacer
Keren Winmill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sustainability, plastics and Brexit: Keynote speakers set to inspire at PPMA Total Show 2019

Experts from IKEA, the British Plastics Federation and The Sunday Times to create a forum for education, knowledge-sharing and debate
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement